<%server.execute "isdev.asp"%> Early post-operative hemodynamic perturbation associated with topiramate-induced metabolic acidosis: A case report Singh S, Banik S, Goyal K, Dube SK - J Pediatr Neurosci
home : about us : ahead of print : current issue : archives search instructions : subscriptionLogin 
Users online: 73      Small font sizeDefault font sizeIncrease font size Print this page Email this page


 
  Table of Contents    
CASE REPORT
Year : 2018  |  Volume : 13  |  Issue : 2  |  Page : 221-223
 

Early post-operative hemodynamic perturbation associated with topiramate-induced metabolic acidosis: A case report


1 Dept of Neuroanaesthesiology and Critical Care, AIIMS, New Delhi, India, India
2 Clinical fellow Neuroanaesthesia, Toronto Western Hospital, Toronto, Canada

Date of Web Publication5-Jul-2018

Correspondence Address:
Keshav Goyal
Dept of Neuroanaesthesiology and Critical Care, AIIMS, New Delhi
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JPN.JPN_86_17

Rights and Permissions

 

   Abstract 


Topiramate is a potent antiepileptic drug with multiple modes of action including inhibition of carbonic anhydrase activity. Inhibition of this enzyme predisposes to non-anion gap metabolic acidosis which has been amply described in the literature. However, the severity is yet to be well defined. We encountered a case of topiramate-induced non-anion gap metabolic acidosis associated with hemodynamic perturbations in an 8-year-old child in the postoperative period.


Keywords: Acidosis, perioperative, seizures, topiramate


How to cite this article:
Singh S, Banik S, Goyal K, Dube SK. Early post-operative hemodynamic perturbation associated with topiramate-induced metabolic acidosis: A case report. J Pediatr Neurosci 2018;13:221-3

How to cite this URL:
Singh S, Banik S, Goyal K, Dube SK. Early post-operative hemodynamic perturbation associated with topiramate-induced metabolic acidosis: A case report. J Pediatr Neurosci [serial online] 2018 [cited 2022 Jan 27];13:221-3. Available from: https://www.pediatricneurosciences.com/text.asp?2018/13/2/221/235964





   Introduction Top


Topiramate, a novel antiepileptic drug (AED) is known to induce non-anion gap (AG) metabolic acidosis and has been extensively quoted in literature.[1],[2],[3],[4],[5],[6],[7] The most likely explanation for this complication is due to urinary bicarbonate loss secondary to inhibition of renal cortical carbonic anhydrase (CA) isoenzymes.[8] The nature of acidosis is usually benign and reverts after the cessation of drug therapy. However, it has potential to cause florid symptoms even to the extent of intervention. We encountered a case of topiramate-induced severe metabolic acidosis in which the patient developed unstable hemodynamics in the early post-operative period following decompressive craniectomy.


   Case Report Top


An 8-year-old child (25kg) was admitted in our intensive care unit (ICU) for elective ventilation following decompressive craniectomy for acute right fronto-temporo-parietal subdural hematoma. On ICU admission (Day 0), the Glasgow coma scale (GCS) was E3VTM4, blood pressure (BP) was 102–106/ 58–60mm Hg, heart rate (HR) was 108–122 beats/min, and oxygen saturation (SpO2) of 99–100% at FiO2 was 0.4. Arterial blood gas (ABG) analysis showed non-AG mild metabolic acidosis with normal lactate levels [Table 1]. The patient had history of generalized tonic-clonic seizure (GTCS) for last 2 years and had been regularly taking tablet lacosamide 100mg twice daily, topiramate 100mg twice daily, and clobazam 10mg once daily.
Table 1: Showing progression of ABG values and serum urea and creatinine in the postoperative period

Click here to view


All AEDs were restarted in the postoperative period (Day 1) through a nasogastric tube. Day 1 hemodynamic parameters were also stable (BP was 98–104mm Hg, HR was 100–104 beats/min). ABG yet again showed non-AG mild metabolic acidosis [Table 1]. Thinking it to be normal saline (O.9% NS) induced hyperchloremic metabolic acidosis (serum chloride- 110 mmol/l), it was stopped and substituted with plasma-lyte A (low chloride content: 95 mmol/l). However, on day 2 and day 3 the acidosis worsened progressively with associated hypotension on day 3 (BP was 80–82/45–47mm Hg and HR was 108–110/min). Volume status, body temperature, serum lactate levels, blood sugar levels, and urine output (average 15ml/hour) were within normal limits. Serum electrolytes were also within normal limits except slight fall in serum sodium (129 mmol/l). Total leucocytic count (TLC) was raised marginally on day 1 (12,200/mm3) and day 2 (12,550/mm3) but remained within normal limits thereafter. Chest radiograph did not reveal any pathology. A computed tomogram (CT) scan of the brain was done, which did not reveal any new onset of ischemia, hemorrhage or worsening of edema. Low-dose noradrenaline (1.25 mcg/min) infusion was initiated to correct hypotension. Speculating topiramate to be the cause of this acidosis, we stopped it and started tab levetiracetam 250mg twice daily. ABG on day 4 and day 5 still showed non-AG metabolic acidosis [Table 1], however, improved. Meanwhile, on day 5, noradrenaline was stopped following stabilization of BP. On day 6, the ABG showed normal acid-base status [Table 1]. The patient was also stable hemodynamically. However, there was no further improvement in neurological status. As such, tracheostomy was done on day 7. The patient was gradually weaned off the ventilator (room air) and discharged on day 13 with GCS-E4VTM5.


   Discussion Top


Topiramate is an atypical newer antiepileptic used for the treatment of GTCS and is being increasingly used in refractory status epilepticus with a high response rate. Along with weak inhibitory activity on CA, it also blocks voltage-dependent sodium channels, potentiates gamma-aminobutyrate receptors, and antagonizes glutamate receptor subtype kainate receptors.[9] Probably its anti-CA activity results in somnolence, nephrolithiasis, paresthesia and metabolic acidosis. Although symptomatic metabolic acidosis is a rare consequence of topiramate therapy, the same might manifest with hemodynamic perturbations. In our case, day 0 and day 1 ABG showed mild non-AG metabolic acidosis which could have been actually a presentation of chronic topiramate therapy. When topiramate was restarted on day 1, the acidosis worsened on day 2 and day 3 along with hypotension on day 3 probably under the effects of inflammatory, metabolic changes, and endocrine changes that accompanies severe head injury. Post-surgical stress could have been another aggravating factor. Only when the offending agent was stopped, the normal acid-base status was restored after an interval of about 72 hours. Simultaneously, the hemodynamic parameters were also stabilized leading to the cessation of inotropic support.

In our patient, continuous infusion of midazolam (1mg/hr) and fentanyl (20 mcg/hr) were started in ICU as sedation. Although high dose midazolam (200 mcg/kg/min) has been reported to cause non-AG metabolic acidosis in pediatric status epilepticus,[10] the midazolam infusion dose in our patient was too low to cause metabolic acidosis. Again, 0.9% NS as a possibility was also ruled out when the serum chloride levels attained normal values after replacing NS with plasma-lyte A (isotonic). Moreover, our patient did not have episodes of diarrhea and thus safely excluded as a possibility of non-AG metabolic acidosis. Again, there was no history of administration of calcium chloride, magnesium chloride or amino acid solutions.

It is a matter of curiosity as to what increases the susceptibility to topiramate-induced metabolic acidosis in only a few patients. As topiramate has a different power of inhibition over each CA isoenzyme, it seems reasonable to assume that differences between CA isoenzymes activity expression in different people could exist. Maybe this could explain the apparent diversity of susceptibility to metabolic acidosis in different persons. Ozer et al. proposed that the acidosis may be the resultant effect of an idiosyncratic reaction or rapid increment in dose.[6] Our patient achieved normal acid- base status after 72 hours of stoppage of topiramate similar to cases reported by Stowe et al.[2] and Fakhoury et al.[4]

Various factors have been mentioned in literature as aggravating factors for topiramate-induced metabolic acidosis. These include concomitant CA inhibitors (acetazolamide), surgery, anesthesia, ketogenic diet, renal disease, dialysis, and diarrhea.


   Conclusion Top


Since topiramate is a widely used drug, anaesthesiologists and critical care physicians should be aware of its potential complication that can be deleterious particularly during the perioperative period. Timely diagnosis and prompt intervention can prevent undue catastrophes.

Name of Institute Where Study Carried Out: Dept of Neuroanaesthesiology and Critical Care, JPNATC, AIIMS, New Delhi, India.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Wilner A, Raymond K, Pollard R. Topiramate and metabolic acidosis. Epilepsia 1999;13:792-5.  Back to cited text no. 1
    
2.
Stowe CD, Bollinger T, James LP, Haley TM, Griebel ML, Farrar HC 3rd. Acute mental status changes and hyperchloremic metabolic acidosis with long-term topiramate therapy. Pharmacotherapy 2000;13:105-9.  Back to cited text no. 2
    
3.
Takeoka M, Holmes GL, Thiele E, Bourgeois BF, Helmers SL, Duffy FH, Riviello JJ. Topiramate and metabolic acidosis in pediatric epilepsy. Epilepsia 2001;13:387-92.  Back to cited text no. 3
    
4.
Fakhoury T, Murray L, Seger D, McLean M, Abou-Khalil B. Topiramate overdose: Clinical and laboratory features. Epilepsy Behav 2002;13:185-9.  Back to cited text no. 4
    
5.
Takeoka M, Riviello JJ Jr, Pfeifer H, Thiele EA. Concomitant treatment with topiramate and ketogenic diet in pediatric epilepsy. Epilepsia 2002;13:1072-5.  Back to cited text no. 5
    
6.
Ozer Y, Altunkaya H. Topiramate induced metabolic acidosis. Anaesthesia 2004;13:830.  Back to cited text no. 6
    
7.
Shiber JR. Severe non-anion gap metabolic acidosis induced by topiramate: A case report. J Emerg Med 2010;13:494-6.  Back to cited text no. 7
    
8.
Mirza N, Marson AG, Pirmohamed M. Effect of topiramate on acid-base balance: Extent, mechanism and effects. Br J Clin Pharmacol 2009;13:655-61.  Back to cited text no. 8
    
9.
Markind JE. Topiramate: A new antiepileptic drug. Am J Health Syst Pharm 1998;13;2:554-62.  Back to cited text no. 9
    
10.
Federman MD, Kelly R, Harrison RE. Refractory metabolic acidosis as a complication of high-dose midazolam infusion for pediatric status epilepticus. Clin Neuropharmacol 2009;13:340-1.  Back to cited text no. 10
    



 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
 
 
  Search
 
  
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (202 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
   Introduction
   Case Report
   Discussion
   Conclusion
    References
    Article Tables

 Article Access Statistics
    Viewed1824    
    Printed67    
    Emailed0    
    PDF Downloaded61    
    Comments [Add]    

Recommend this journal